MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

MRK · NYSE

Merck & Company, Inc. Common Stock (new)

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$131.82As of Jul 28, 2026
Market capitalization$326B
52-week range$76.66–$132.53
S&P 500 portfolio weight0.51%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$100.00-24.1% vs. reference
Average$136.35+3.4% vs. reference
High$155.00+17.6% vs. reference
12 Buy5 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 4, 2026Jun 2026
Consensus EPS-$0.263 estimates
Expected range-$0.36–-$0.21Low to high EPS
Dec 2026$2.74Street EPS consensus
Dec 2027$9.72Street EPS consensus
Dec 2028$11.06Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+1.3% YoY$65.01B$64.17B
Operating income$21.22B$19.91B
Net income$18.25B$17.12B
Operating cash flow$16.47B$21.47B
Capital expenditures($4.11B)($3.37B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings

BNK Invest

Notable ETF Inflow Detected - XLV, MRK, AMGN, GILD

Zacks

Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.